However, due to heterogeneity of HNSCC lesions, targeting HIF-1α might not be sufficient to improve a therapeutic effect of anti-EGFR treatment on hypoxic tumors. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.